RxDoctor Payments Data

Ronald Asay

Cardiovascular Disease · Orem, UTNPI 1578521308

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (38.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Boston Scientific at 39.9% of the total. Reporting peaked in 2019 at $3,641 and has fallen 93.4% since, to $239 in 2023.

$7,725in general payments, 2019–2025

Across 97 payments — averaging $79.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Merit Medical Systems Inc$2K
  • Medtronic$1K
  • Amgen$125
  • Novartis$117
  • Johnson & Johnson$113
  • plus $620 from 14 others

What the payments were for

  • Consulting fees$2,24729%
  • Speaking & faculty fees$3,00039%
  • Travel & lodging$471%
  • Food & beverage$2,43131%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,725 in reported general payments places this provider in the 75th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Other cardiovascular disease in Orem

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →